- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04495608
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels (FLUCOLITH)
Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults.
Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular reabsorption of calcium due to increased active vitamin D, i.e. 1,25(OH)2D, levels. The management of hypercalciuria is challenging. Classic management based on hyperhydration and dietary advice has low impact on calciuria and therefore on CKD progression. Other strategies such as hydrochlorothiazide can be proposed, however with an uncertain medical benefit in view of side effects (hypokalemia, asthenia, potential cutaneous long-term side effects).
Azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels. These antifungal drugs are commonly used in neonates, infants and adults; pharmacokinetic data are well described. Recently, to improve azoles tolerance, fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 mutation (1 adult) or NPTIIc mutations (1 child), while maintaining a stable renal function. Based on these observations, the investigators hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels.
The primary objective is to demonstrate that fluconazole normalizes or decreases calciuria after 18 weeks of treatment in patients with hypercalciuria and increased 1,25(OH)2D levels.
The secondary objectives aim to describe:
- the effects of fluconazole on the evolution over time of the calcium/phosphate metabolism,
- the evolution of renal function,
- the cohort at Baseline and after 4 months of treatment period,
- the safety of fluconazole,
- the onset of potential mycological resistances,
- and the treatment compliance. This is a prospective, interventional, national, randomized in 2 parallel groups (1:1), controlled versus placebo, double blind trial.
This study will involve patients between 10 and 60 years of age suffering from nephrolithiasis and/or nephrocalcinosis with hypercalciuria (> 0.1 mmol/kg/d) and increased 1,25 (OH)2D levels (≥ 150 pmol/l) and 25-OH-D levels (≥50 nmol/L).
FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug (e.g. fluconazole) in rare renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients.
If the results of this proof-of-concept randomized controlled trial are positive, the investigators will propose an extension phase to evaluate the long term efficacy and safety of fluconazole on renal and bone parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Aurélia BERTHOLET-THOMAS, Dr
- Phone Number: +33 4 27 85 61 04
- Email: aurelia.bertholet-thomas@chu-lyon.fr
Study Contact Backup
- Name: Justine BACCHETTA, Pr
- Email: justine.bacchetta@chu-lyon.fr
Study Locations
-
-
-
Bron, France, Bron
- Not yet recruiting
- Service de Néphrologie Rhumatologie Dermatologie Pédiatrique
-
Contact:
- Aurélia BERTHOLET-THOMAS
- Phone Number: +33 4 27 85 61 04
- Email: aurelia.bertholet-thomas@chu-lyon.fr
-
Lyon, France
- Not yet recruiting
- Hôpital Edouard Herriot
-
Contact:
- Sandrine LEMOINE, Dr
- Email: sandrine.lemoine@chu-lyon.fr
-
Principal Investigator:
- Sandrine LEMOINE, Dr
-
Paris, France, 75743
- Recruiting
- Hopital Universitaire Necker
-
Contact:
- Bertrand KNEBELMANN, Pr
- Email: bertrand.knebelmann@aphp.fr
-
Principal Investigator:
- Bertrand KNEBELMANN, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who presented in their medical history nephrolithiasis and/or nephrocalcinosis
Patients who have at inclusion (V1), a local biological evaluation with:
- 24-hour urine calcium > 0.1 mmol/kg/day,
- and 1,25(OH)2D levels ≥ 150 pmol/L,
- and 25-OH-D levels ≥ 20 nmol/L,
- and calcemia levels ≤ 2.65 mmol/L.
- Children from 10 years
- Adults until 60 years
- Women of child-bearing potential (including sexually active adolescent females) must use highly effective methods of contraception (Annex 7 CTFG recommendations) during the study period. Likewise, partners of male patients of child-bearing potential must use highly effective methods of contraception. Male patients must use condoms.
- Patients insured or beneficiary of a health insurance plan
- Evidence of signed and dated informed consent document(s) indicating that the subject and/or his parents/legal guardian has/have been informed of all pertinent aspects of the trial.
Exclusion Criteria:
- Patient who already received fluconazole or ketoconazole during the last 6 months before inclusion
- Patient weight below than 28 kg
- Patient with BMI >35
- Women menopaused
- Patients who cannot stop hydrochlorothiazide or other diuretics during the screening and study period
- Patients who cannot stop vitamin D supplementation and/or calcium supplementation (drugs, enriched waters, etc.) during the study period
- Hypersensibility to fluconazole and/or other derivative azoles and/or excipients
- Due to the presence of lactose excipient, patients presenting rare hereditary abnormalities of galactose intolerance, of Lapp lactase deficit or of glucose-galactose malabsorption
- Patients who need co-administration with other drugs known to prolong the QT interval and metabolized by cytochrome P450 (CYP) 3A4 (pimozide, quinidine and erythromycin; the exhaustive list of drugs known to prolong the QTc is available on: https://crediblemeds.org).
- Patients with iatrogenic hypercalciuria (vitamin D intoxication, immobilization)
Relating to the risk of QT interval prolongation:
- congenital Long QT syndrome;
- familial history of sudden cardiac death before 50 years of age;
- cardiopathy: ischemia or myocardial infarction, congestive cardiac insufficiency, left ventricle hypertrophy, cardiomyopathy, conduction trouble within 6 months preceding the inclusion;
- arrhythmia history (in particular ventricular arrhythmia, auricular fibrillation or recent rhythm recovery after an auricular fibrillation);
- electrolytic instabilities: hypokalemia, hypomagnesemia, hypocalcemia ;
- bradycardia (< 50 beats per minute) ;
- acute neurological events (i.e. intracranial hemorrhage or sub-arachnoid, cerebrovascular accident, intracranial trauma) within 6 months preceding the inclusion;
- adult patients with a QT interval/corrected QT interval > 470ms for women and > 450ms for men at the ECG performed at the inclusion visit (V1). For children from 10 years, the QT interval/corrected QT interval should be > 460ms for girls and > 450ms for boys.
- Children with a history of cardiac pathology
- Patients with an estimated glomerular filtration rate < 60 mL/min/1.73m²
- Patients with a liver disease or an abnormality in the initial liver lab test
- Patients with enuresis
- Patients with another cause of identified lithiasis
- Patients suffering from granulomatosis pathology such as sarcoidosis
- Patient with hyperparathyroidism
- Women who are pregnant or breast feeding, or who have a project of pregnancy before the end of the study
- Patients with a project of travelling in a sunny area during the study period
- Immunodeficient patients
- Patients with other diseases or disorders that could preclude assessment
- Patient who is participating in another research study that may interfere with the results or conclusions of this study
- Patients under judicial protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fluconazole
Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
|
Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :
The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6). During the titration period, if 24-hours calciuria is > 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable. After W6 and until the end of the study, the treatment dose will remain stable (stable period). |
Placebo Comparator: placebo
Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
|
Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with normalization of calciuria
Time Frame: Baseline (V1) and 18 weeks of treatment (V7)
|
Proportion of patients with normalization of 24-hour calciuria (≤ 0.1 mmol/kg/d) between Baseline (V1) and W18 (V7), or with a relative change of 30% of 24-hour calciuria between Baseline (V1) and W18 (V7) for patients who still have at W18 a 24-hour calciuria> 0.1mmol/kg/d.
|
Baseline (V1) and 18 weeks of treatment (V7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantity of calcium intakes
Time Frame: 18 weeks
|
Anthropometry
|
18 weeks
|
Quantity of sodium intakes
Time Frame: 18 weeks
|
Anthropometry
|
18 weeks
|
Quantity of protein intakes
Time Frame: 18 weeks
|
Anthropometry
|
18 weeks
|
bone alkaline phosphatases
Time Frame: 16 weeks
|
Bone evaluation with biomarkers
|
16 weeks
|
FGF23
Time Frame: 16 weeks
|
Bone evaluation with biomarkers
|
16 weeks
|
femoral neck (FN) assessed with Dual energy x-ray absorptiometry (DXA):
Time Frame: at randomization (day 0)
|
Bone evaluation with biomarkers
|
at randomization (day 0)
|
lumbar spine vertebra 2 to 4 (LS2-4) areal bone mineral density assessed with Dual energy x-ray absorptiometry (DXA):
Time Frame: at randomization (day 0)
|
Bone evaluation with biomarkers
|
at randomization (day 0)
|
total body (TB) areal bone mineral density assessed with Dual energy x-ray absorptiometry (DXA):
Time Frame: at randomization (day 0)
|
Bone evaluation with biomarkers
|
at randomization (day 0)
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Hepatic functions : aspartate transaminase
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Hepatic functions : bilirubin
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Hepatic functions : gamma-glutamyl-transpeptidase
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Lactate dehydrogenase
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
phosphoremia
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Calcemia
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Serum creatinine
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Albumin
|
20 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 18 weeks
|
Hepatic functions : alanine aminotransferase
|
18 weeks
|
Safety evaluation through the study : blood analysis
Time Frame: 20 weeks
|
Complete blood cell counts
|
20 weeks
|
Proportion of patients that developed mycological resistance
Time Frame: 18 weeks
|
Mycological urine samples will be collected to evaluate the onset of potential mycological resistances to Candida.
A description of the proportion of patients that developed at least one mycological resistance into the study will be performed by treatment arm, with a listing of the given resistances.
|
18 weeks
|
Proportion of patients that developed mycological resistance
Time Frame: 18 weeks
|
Mycological buccal samples will be collected to evaluate the onset of potential mycological resistances to Candida.
A description of the proportion of patients that developed at least one mycological resistance into the study will be performed by treatment arm, with a listing of the given resistances.
|
18 weeks
|
Evolution over time of the calcium/phosphate metabolism (serum and urines dosages)
Time Frame: Baseline (V1), 18 weeks of treatment (V7)
|
Serum: calcium, ionized calcium, phosphate, magnesium, PTH, 25-OH-D, 1,25(OH)2D, 24-25 (OH)2 D, 25-OH-D:24-25(OH)2D ratio, total alkaline phosphatase.
|
Baseline (V1), 18 weeks of treatment (V7)
|
Serum creatinine
Time Frame: Baseline (V1), 18 weeks of treatment (V7)
|
Evolution of renal function
|
Baseline (V1), 18 weeks of treatment (V7)
|
number of lithiasis, nephrocalcinosis
Time Frame: Baseline (V1), 18 weeks of treatment (V7)
|
Evolution of renal function
|
Baseline (V1), 18 weeks of treatment (V7)
|
size of lithiasis, nephrocalcinosis
Time Frame: Baseline (V1), 18 weeks of treatment (V7)
|
Evolution of renal function
|
Baseline (V1), 18 weeks of treatment (V7)
|
Klotho
Time Frame: 18 weeks
|
Bone evaluation with biomarkers
|
18 weeks
|
Safety evaluation through the study : cardiac evaluation
Time Frame: Baseline (V1)
|
Cardiac evaluation : electrocardiogram, corrected QT interval
|
Baseline (V1)
|
Safety evaluation through the study : cardiac evaluation
Time Frame: 4 weeks
|
Cardiac evaluation : electrocardiogram, corrected QT interval
|
4 weeks
|
Safety evaluation through the study : cardiac evaluation
Time Frame: 10 weeks
|
Cardiac evaluation : electrocardiogram, corrected QT interval
|
10 weeks
|
Compliance assessment
Time Frame: every month from Randomization (V2) to 18 weeks of treatment (V7)
|
Compliance under treatment (fluconazole or placebo) will be measured by accountability of returned study treatment and information recorded on patients' diary.
Level of compliance will be described separately at several follow-up times
|
every month from Randomization (V2) to 18 weeks of treatment (V7)
|
Quality of life and treatment satisfaction assessments : adults
Time Frame: The endpoint will be the variation of total score between Randomization (V2) and 18 weeks of treatment (V7)
|
Quality of life will be assessed with SF-36 auto-questionnaire (for adult patients)
|
The endpoint will be the variation of total score between Randomization (V2) and 18 weeks of treatment (V7)
|
Quality of life and treatment satisfaction assessments : children and adolescents
Time Frame: The endpoint will be the variation of total score between Randomization (V2) and 18 weeks of treatment (V7)
|
PedsQL auto-questionnaire (PedsQL 8-12 years for children, and PedsQL 13-18 years for adolescents).
|
The endpoint will be the variation of total score between Randomization (V2) and 18 weeks of treatment (V7)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aurélia BERTHOLET-THOMAS, Dr, Hospices Civils de Lyon
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Urological Manifestations
- Pathological Conditions, Anatomical
- Calcium Metabolism Disorders
- Urolithiasis
- Urinary Calculi
- Calculi
- Calcinosis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Calculi
- Nephrolithiasis
- Hypercalciuria
- Nephrocalcinosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluconazole
Other Study ID Numbers
- 69HCL20_0071
- 2020-003011-97 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrolithiasis
-
Mayo ClinicCompletedNephrolithiasis, Calcium Oxalate | Nephrolithiasis, Calcium PhosphateUnited States
-
University Hospital Inselspital, BerneCompletedCalcium NephrolithiasisSwitzerland
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnUric Acid NephrolithiasisUnited States
-
University of British ColumbiaRecruiting
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingKidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
Mahidol UniversityNot yet recruitingSafety Issues | Surgery-Complications | Nephrolithiasis Staghorn CalculusThailand
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Himalaya...CompletedCystinuria | Nephrolithiasis, Calcium OxalateUnited States
-
Ai PengUnknown
Clinical Trials on Fluconazole
-
AstraZenecaCompletedAsthmaUnited States, Canada, Denmark, France, Italy, Sweden, United Kingdom, Belgium, Taiwan, Brazil, Poland, Russian Federation, Spain, Germany, Argentina, Colombia, Mexico
-
National Hospital for Tropical Diseases, Hanoi,...Centers for Disease Control and Prevention; Hospital for Tropical Diseases,...UnknownHIV/AIDS | Mycosis Fungoides | Cryptococcosis | Cryptococcal Meningitis | Opportunistic Infections, HIV Related | Mycosis; OpportunisticVietnam
-
Radboud University Medical CenterSt. Antonius HospitalCompletedObesity | Candidiasis | Invasive Fungal Infections | FluconazoleNetherlands
-
Daniel BenjaminPediatric Pharmacology Research Units NetworkCompletedCandidiasisUnited States
-
BayerCompletedPharmacology, ClinicalGermany
-
PfizerCompleted
-
Anders Rane, MD, PhD, Senior professorKarolinska University HospitalCompletedBacterial Infections and Mycoses | Ductus Arteriosis, PatentSweden
-
Makerere UniversityGilead Sciences; University of MinnesotaRecruitingCryptococcal MeningitisUganda
-
F2G Biotech GmbHThe Clinical Trials Centre Cologne; Klinik für Hämatologie, Aachen; Medizinische...Withdrawn
-
Benha UniversityRecruiting